ClinicalTrials.gg
CompletedNCT06527144Updated Apr 11, 2025

A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Phase 2 interventional study of 3mg TQC3721 Suspension for Inhalation and 6mg TQC3721 Suspension for Inhalation in Pulmonary Disease, Chronic Obstructive, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 28 sites in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited — 2 open to participants now, 6 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sino Biopharmaceutical Limited.

Enrollment
5th of 17
240 · median 113
Started
2024
with 5 others
Phase 2
8 of 17
none open now
Registered
8th of 17
by date

Among the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, this one is the 5th largest by enrollment, is one of 6 that started in 2024, is one of 8 in phase 2, and was the 8th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign before the test and fully understand the test content, process and possible adverse reactions.
  • Male and female subjects aged 40 to 80 years old (including the cut-off value).
  • (BMI) in the range of 18-30kg/m2 (including the critical value)
  • Subjects have no pregnancy plan and voluntarily use effective for at least 1 month from screening to the last use of the study drug.
  • Diagnosed as a patient according to the The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 criteria.
  • Able to conduct acceptable and reproducible lung function tests.
  • COPD clinical stability within the 4 weeks prior to screening visit (V1 visit) and between V1 visit and V2 visit.
  • Smoking history ≥ 10 pack years.

Exclusion criteria

Exclusion Criteria:

  • History of life-threatening , including admission to the intensive care unit and/or the need for intubation.
  • Screening for COPD acute exacerbations that require systemic hormone therapy prior to the visit.
  • Screening for hospitalization history due to COPD within the first 6 months.
  • Use antibiotics for respiratory tract infections within 6 weeks prior to screening or randomization visit.
  • Chest computed tomography (CT) revealed abnormalities and concluded that the abnormalities were not caused by COPD.
  • Previous lung resection or lung reduction surgery.
  • Pulmonary rehabilitation treatment.
  • Previously received TQC3721 treatment.
  • Patients who received immunotherapy within the first 4 weeks of the screening period.
  • The patient has a history of diseases that are currently beyond their control.
  • History or current evidence of cardiovascular disease with clinical significance.
  • History of cured or untreated malignant tumors in any organ or system within the past 5 years.
  • Screening for clinically significant safety laboratory test outliers determined by the researcher during the visit.
  • Those who require oxygen therapy or intermittent oxygen therapy.
  • Receive attenuated within 28 days prior to randomization, inactivated vaccine within 7 days, or study.
  • Planned vaccine recipients during the period.
  • Individuals who have participated in any drug or medical device clinical trials prior to screening.
  • Researchers believe that there are other situations that are not suitable for participation in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    3mg TQC3721 Suspension for Inhalation (Twice a day)

    Two syringes of TQC3721 suspension for inhalation (1ml:1.5mg), twice a day for 4 weeks.

    Drug: 3mg TQC3721 Suspension for Inhalation

  • Experimental
    6mg TQC3721 Suspension for Inhalation (Twice a day)

    one syringe of TQC3721 suspension for inhalation(1ml:6mg)and one TQC3721 suspension placebo for inhalation (1ml:0mg), twice a day for 4 weeks.

    Drug: 6mg TQC3721 Suspension for Inhalation

  • Placebo comparator
    Placebo for TQC3721 Suspension for Inhalation (Twice a day)

    Two syringes of placebo for TQC3721 suspension for inhalation (1ml:0mg), twice a day for 4 weeks.

    Drug: Placebo TQC3721 suspension for inhalation

Interventions

  • Drug3mg TQC3721 Suspension for Inhalation

    TQC3721 suspension for inhalation is target inhibitor.

  • Drug6mg TQC3721 Suspension for Inhalation

    TQC3721 suspension for inhalation is target inhibitor.

  • DrugPlacebo TQC3721 suspension for inhalation

    Placebo without active drug substance.

06

What researchers measure

Primary outcomes

  1. Change of the maximum value of Forced Expiratory Volume in the first second (FEV1)

    Change of the maximum value of FEV1 was determined from baseline to four weeks after treatment.

    Time frame: From baseline to four weeks after treatment

Secondary outcomes

  1. Change of the mean value of FEV1

    Compared with baseline, the mean value of FEV1 was changed within 3 hours and 12 hours after morning medication at 4 weeks of treatment.

    Time frame: From baseline to four weeks after treatment

  2. Changes in peak FEV1 values,trough FEV1 values, mean value within 3 hours after administration

    Compared with baseline, Changes in peak FEV1 values,trough FEV1 values, mean value within 3 hours after administration after 2 weeks of treatment.

    Time frame: From baseline to two weeks after treatment

  3. Rescue medication

    Frequency of Rescue medication use during the study compared to placebo group

    Time frame: From baseline to four weeks after administration

  4. Adverse Events (AE)

    The number, frequency, incidence, and severity of adverse events, serious adverse events, and adverse events associated with investigational drugs (including investigational drugs and control drugs), as well as abnormal laboratory indicators were evaluated.

    Time frame: From baseline to safety visit (about 5 weeks after first dosing).

  5. Changes in the peak value of FEV1,mean value of FEV1 within 3 hours and 12 hours after administration

    Compared with baseline, changes in the peak value of FEV1 after 1 day of treatment, and the mean value of FEV1 within 3 hours and 12 hours after administration.

    Time frame: From baseline to 1day after treatment

  6. Changes of FEV1 at each time point

    Changes in series FEV1 at each time point within 12 hours after morning administration on day 1 of treatment (after first dosing) compared to baseline.

    Time frame: From baseline to 1day after treatment

  7. Changes in peak value of FEV1 and the mean value of FEV1 within 3 hours and 12 hours

    To evaluate the change in FEV1 peak value and FEV1 mean value within 3 hours and 12 hours after 4 weeks of treatment compared with 1 day of treatment (after first administration)

    Time frame: From 1day after treatment to 4 weeks after treatment

  8. Changes in Morning Valley FEV1

    Changes in Morning Valley FEV1 after 4 weeks of treatment compared with baseline

    Time frame: From baseline to four weeks after treatment

  9. Changes in Modified Medical Research Council (mMRC) Dyspnea Scale Score

    mMRC Dyspnea Scale Score's total score is 0-4 points, with the higher score meaning the more severe symptoms.

    Time frame: Changes in mMRC score after 2 and 4 weeks of treatment compared with baseline

  10. Chronic obstructive pulmonary disease Assessment Test (CAT)

    There are 8 questions in the CAT, and each question is scored 0-5 points, with the higher score meaning the more severe symptoms

    Time frame: Changes in CAT assessment after 2 and 4 weeks of treatment compared with baseline

  11. St. George's Respiratory Questionnaire (SGRQ)

    SGRQ has three parts: symptoms, abilities, and effects, and is used to comprehensively measure the physical, mental, and social status of COPD patients.

    Time frame: Changes in SGRQ after 2 and 4 weeks of treatment compared with baseline

  12. Basic Dyspnea Index (BDI)

    BDI has three levels: functional impairment, magnitude of task, and magnitude of effort. Each level is rated from 0 (severe) to 4(No damage).

    Time frame: Changes in BDI after 2 and 4 weeks of treatment compared with baseline.

  13. Transitional Dyspnea Index (TDI)

    TDI has three levels:changes in functional impairment, changes in magnitude of task, changes in magnitude of effort,. Scores in each area range from -3 (significant deterioration) to 0 (no change) to +3 (significant improvement).

    Time frame: Changes in TDI after 2 and 4 weeks of treatment compared with baseline

07

Study locations

28 sites
  • Fu Yang People'S Hospital
    Fuyang, Anhui 236000, China
  • ChongQing University Fuling Hospital
    Chongqing, Chongqing Municipality 400000, China
  • The Second Affiliated Hospital of Xiamen Medical College
    Xiamen, Fujian 361021, China
  • The First Hospital of Lanzhou University
    Lanzhou, Gansu 730000, China
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510120, China
  • The People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530016, China
  • Zunyi Medical University Affiliated Hospital
    Zunyi, Guizhou 563000, China
  • Cangzhou Hospital of Integrated Tcm-Wm·Hebei
    Cangzhou, Hebei 61012, China
  • The Third Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050051, China
  • Puyang Oilfield General Hospital
    Puyang, Henan 457001, China
  • Shangqiu First People's Hospita
    Shangqiu, Henan 476000, China
  • Chifeng Municipal Hospital
    Chifeng, Inner Mongolia 024000, China
  • Wuxi Fifth People's Hospital
    Wuxi, Jiangsu 214000, China
  • Yixing People'S Hospital
    Wuxi, Jiangsu 214200, China
  • Northern Jiangsu People's Hospital
    Yangzhou, Jiangsu 225000, China
  • Jiangxi Provincial People's Hospital
    Nanchang, Jiangxi 330006, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130031, China
  • Siping Central People's Hospital
    Siping, Jilin 136099, China
  • Genertec Liaoyou Gem Flower Hospital
    Panjin, Liaoning 100007, China
  • Heze Municipal Hospital
    Heze, Shandong 274031, China
  • Shanghai JiaoTong University of medicine Ruijin Hospital
    Shanghai, Shanghai Municipality 20025, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi 030000, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610044, China
  • Suining Central Hospital
    Suining, Sichuan 629000, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality 300041, China
  • TianJin 4th Center Hospital
    Tianjin, Tianjin Municipality 300142, China
  • The First Affiliated Hospital of Shihezi University
    Shihezi, Xinjiang 832000, China
  • Wenzhou University Affiliated Second Hospital
    Wenzhou, Zhejiang 325027, China
08

References and documents

Publications

  • He LX, Yang L, Xiao ZK, Qiu R, Yu FM, Wu LQ, Zhang WH, Liu XC, Min LF, Ma XQ, Jiang JZ, Yuan B, Dai RR, Liu D, Li XH, Wang T, Cao J, Luo XB, Liu XJ, Chen C, Li WG, Yu D, Luo Z, Li WM; PACER-II Trial Investigators. Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients With COPD in China (PACER-II): A Phase 2, Multicenter, Randomized, Double-Anonymized, Placebo-Controlled Trial. Chest. 2026 Jun;169(6):1536-1550. doi: 10.1016/j.chest.2025.12.055. Epub 2026 Mar 3. PubMed 41812987 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Jan 2025, 4 months.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 4 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2024
First posted
Jul 30, 2024
StartActual
Sep 14, 2024
Primary completionActual
Jan 16, 2025
CompletionActual
Mar 6, 2025
Last update
Apr 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06527144
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Sep 14, 2024
Primary completion
Jan 16, 2025
Completion
Mar 6, 2025
Last update
Apr 11, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion